Strongbridge Biopharma (SBBP) Trading Down 0.6%

Share on StockTwits

Strongbridge Biopharma plc (NASDAQ:SBBP)’s share price traded down 0.6% during mid-day trading on Tuesday . The company traded as low as $4.80 and last traded at $5.27. 4,760 shares were traded during mid-day trading, a decline of 99% from the average session volume of 499,343 shares. The stock had previously closed at $5.30.

A number of equities analysts have recently issued reports on the company. BidaskClub upgraded Strongbridge Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, May 5th. ValuEngine upgraded Strongbridge Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd. Zacks Investment Research downgraded Strongbridge Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 12th. Finally, Cantor Fitzgerald set a $14.00 price target on Strongbridge Biopharma and gave the stock a “buy” rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $12.81.

The stock has a market cap of $250.44 million, a price-to-earnings ratio of -3.52 and a beta of 0.93. The company has a debt-to-equity ratio of 41.16, a current ratio of 8.90 and a quick ratio of 8.74.

Strongbridge Biopharma (NASDAQ:SBBP) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.25). The company had revenue of $3.87 million for the quarter, compared to analysts’ expectations of $3.25 million. Strongbridge Biopharma had a negative net margin of 1,032.62% and a negative return on equity of 1,224.30%. analysts expect that Strongbridge Biopharma plc will post -1.97 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp lifted its position in Strongbridge Biopharma by 3.6% during the first quarter. Northern Trust Corp now owns 237,053 shares of the biotechnology company’s stock valued at $2,098,000 after purchasing an additional 8,212 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Strongbridge Biopharma by 25.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 58,000 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 11,600 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new position in Strongbridge Biopharma during the first quarter valued at $119,000. Geode Capital Management LLC raised its holdings in Strongbridge Biopharma by 20.7% during the fourth quarter. Geode Capital Management LLC now owns 79,093 shares of the biotechnology company’s stock valued at $573,000 after acquiring an additional 13,554 shares during the period. Finally, New York State Common Retirement Fund raised its holdings in Strongbridge Biopharma by 125.2% during the first quarter. New York State Common Retirement Fund now owns 25,900 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 14,400 shares during the period. Institutional investors own 67.69% of the company’s stock.

About Strongbridge Biopharma

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.

See Also: Are Wall Street analysts’ stock ratings worth following?

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Anticipate Champions Oncology Inc  to Announce $0.01 EPS
Brokerages Anticipate Champions Oncology Inc to Announce $0.01 EPS
Diplomat Pharmacy Inc  Expected to Post Quarterly Sales of $1.43 Billion
Diplomat Pharmacy Inc Expected to Post Quarterly Sales of $1.43 Billion
BitShares Market Cap Reaches $314.40 Million
BitShares Market Cap Reaches $314.40 Million
PumaPay Price Hits $0.0015 on Major Exchanges
PumaPay Price Hits $0.0015 on Major Exchanges
CarGurus Inc  Expected to Announce Earnings of $0.05 Per Share
CarGurus Inc Expected to Announce Earnings of $0.05 Per Share
Zacks: Analysts Anticipate Costco Wholesale Co.  to Post $2.30 Earnings Per Share
Zacks: Analysts Anticipate Costco Wholesale Co. to Post $2.30 Earnings Per Share


© 2006-2018 Ticker Report. Google+.